Table 1.
Patient characteristics
| Characteristic | New-onset BOS | Non-BOS chronic GVHD | No chronic GVHD | P for BOS vs. non-BOS chronic GVHD | P for BOS vs. no chronic GVHD |
|---|---|---|---|---|---|
| Total number | 33 | 31 | 29 | ||
| Median age at sample draw (range), y | 56 (31–72) | 53 (21–68) | 53 (23–75) | 0.16 | 0.43 |
| Sex | 1.0 | 1.0 | |||
| Male | 19 (58) | 17 (55) | 16 (55) | ||
| Female | 14 (42) | 14 (45) | 13 (45) | ||
| Race | 0.70 | 0.28 | |||
| White | 30 (91) | 27 (87) | 23 (79) | ||
| Others | 3 (9) | 4 (13) | 6 (21) | ||
| Primary diagnosis | 0.26 | 0.69 | |||
| Acute leukemia | 13 (39) | 10 (32) | 15 (52) | ||
| Chronic leukemia | 6 (18) | 1 (3) | 3 (10) | ||
| MDS/MPN | 9 (27) | 14 (45) | 5 (17) | ||
| Lymphoma | 4 (12) | 4 (13) | 4 (14) | ||
| Other | 1 (3) | 2 (6) | 2 (7) | ||
| Stem cell source | 0.83 | 0.19 | |||
| Peripheral blood stem cell | 30 (91) | 28 (90) | 24 (83) | ||
| Bone marrow | 3 (9) | 2 (6) | 2 (7) | ||
| Cord blood | 0 (0) | 1 (3) | 3 (10) | ||
| Conditioning intensity | 1.0 | 0.80 | |||
| Myeloablative | 20 (61) | 18 (58) | 16 (55) | ||
| Reduced intensity | 13 (39) | 13 (42) | 13 (45) | ||
| Donor type | 0.14 | 0.15 | |||
| HLA-matched relative | 18 (55) | 10 (32) | 9 (31) | ||
| HLA-mismatched relative | 1 (3) | 1 (3) | 2 (7) | ||
| Unrelated donor | 14 (42) | 20 (65) | 18 (62) | ||
| A female donor to a male recipient | 11 (33) | 6 (19) | 6 (21) | 0.26 | 0.39 |
| Prior grade II-IV acute GVHD | 17 (52) | 22 (71) | 18 (62) | 0.13 | 0.45 |
| Median months from HCT to sample draw (range) | 18 (5–132) | 18 (5–72) | 13 (9–64) | 0.81 | 0.17 |
| Median months from chronic GVHD to sample draw (range) | 7 (0–90) | 7 (0–66) | NA | 0.55 | NA |
| Steroid treatment at sample draw | 30* (94) | 20 (65) | 3 (10) | 0.005 | <0.001 |
| NIH global severity excluding the lungs | 0.25 | NA | |||
| None or mild | 13 (39) | 19 (61) | NA | ||
| Moderate | 14 (42) | 9 (29) | NA | ||
| Severe | 6 (18) | 3 (10) | NA | ||
| Involved sites other than the lungs | |||||
| Skin | 14 (42) | 11 (35) | NA | 0.62 | |
| Mouth | 15 (45) | 17 (55) | NA | 0.62 | |
| Eye | 27(82) | 16 (52) | NA | 0.016 | |
| Gastrointestinal tract | 5 (15) | 5 (16) | NA | 1.0 | |
| Liver | 3 (9) | 2 (6) | NA | 1.0 | |
| Joint/fascia | 7 (21) | 5 (16) | NA | 0.75 | |
| Genital | 3 (9) | 2 (6) | NA | 1.0 |
*
One patient is excluded due to absence of information.
BOS, bronchiolitis obliterans; NA, not applicable.